IGE025 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
299Cystic fibrosis1

299. Cystic fibrosis


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-006648-23-DE
(EUCTR)
12/11/200815/08/2008An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosisAn exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis.
MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung
MedDRA version: 9.1;Classification code 10000244;Term: ABPA
Trade Name: Xolair 150 mg Pulver und Injektionslösung zur Herstellung einer Injektionslösung
Product Name: Xolair
Product Code: IGE025
INN or Proposed INN: Omalizumab
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
60United Kingdom;Germany;Netherlands;Belgium;Ireland;Italy